News
PHIO
1.080
+1.89%
0.020
Weekly Report: what happened at PHIO last week (0511-0515)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 05/12 12:06
Phio Pharmaceuticals to join Force Family Office fireside chat on skin cancer innovations
PUBT · 05/12 11:04
Weekly Report: what happened at PHIO last week (0504-0508)?
Weekly Report · 05/11 10:00
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Phio Pharmaceuticals (PHIO) and Myomo (MYO)
TipRanks · 05/08 11:10
Phio Pharmaceuticals Q1 net loss widens on higher R&D costs
Reuters · 05/07 20:57
Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate
Benzinga · 05/07 20:51
Phio Pharmaceuticals Q1 FY26 net loss widens to $4 million; R&D expenses rise 215% to $2.8 million
PUBT · 05/07 20:36
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Newsfile · 05/07 20:05
Weekly Report: what happened at PHIO last week (0427-0501)?
Weekly Report · 05/04 09:58
Weekly Report: what happened at PHIO last week (0420-0424)?
Weekly Report · 04/27 10:00
Phio Pharma to present at Renmark virtual non-deal roadshow, hosts live Q&A
PUBT · 04/23 11:04
Weekly Report: what happened at PHIO last week (0413-0417)?
Weekly Report · 04/20 09:57
Phio Pharma To Discuss Cancer Drug Progress In Upcoming Investor Chat, Highlights Early Results For Skin Cancer Treatment Ahead Of Event
Benzinga · 04/13 11:14
Phio Pharmaceuticals to join Force Family Office fireside chat on skin cancer program
PUBT · 04/13 11:03
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Newsfile · 04/13 11:00
Weekly Report: what happened at PHIO last week (0406-0410)?
Weekly Report · 04/13 10:00
Phio CEO to present at Centri Capital Conference, highlighting INTASYL immuno-oncology strategy
Reuters · 04/09 11:05
Phio Pharmaceuticals Establishes New At-the-Market Equity Program
TipRanks · 04/08 21:15
Phio Pharma Enters Into At The Market Offering Agreement With H.C. Wainwright; Phio To Offer Up To $6.36M Of Shares Under Sales Agreement
Benzinga · 04/08 20:36
More
Webull provides a variety of real-time PHIO stock news. You can receive the latest news about Phio Pharmaceuticals Corp through multiple platforms. This information may help you make smarter investment decisions.
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.